Systematic optimization and characterization of the MidTAC platform for targeted protein degradation.

IF 10.4 1区 医学 Q1 CHEMISTRY, MULTIDISCIPLINARY
Yu-Bing Han, Si-Hong Zhong, Ming-Zhi Wang, Zhen-Qian Fu, Yu-Tong Tu, Jia Li, Yu-Bo Zhou
{"title":"Systematic optimization and characterization of the MidTAC platform for targeted protein degradation.","authors":"Yu-Bing Han, Si-Hong Zhong, Ming-Zhi Wang, Zhen-Qian Fu, Yu-Tong Tu, Jia Li, Yu-Bo Zhou","doi":"10.1038/s41401-026-01959-7","DOIUrl":null,"url":null,"abstract":"<p><p>Biological proteolysis-targeting chimeras (BioPROTACs), which employ peptide or protein-based targeting ligands to recruit endogenous degradation machinery, offer a promising strategy to expand the scope of targeted protein degradation. The recently discovered Midnolin employs a distinct, ubiquitin-independent \"capture-degradation\" mechanism that engages the proteasome directly, offering a complementary mechanistic strategy. However, the design principles, domain requirements, and substrate selectivity of Midnolin-based targeting chimeras (MidTAC) remain poorly understood. In this study, we systematically optimized the MidTAC platform and defined its functional boundaries. We demonstrated that optimal degradation activity requires the targeting module, the anti-GFP nanobody VHHGFP4 (variable domain of heavy chain of heavy-chain-only antibody against GFP variant 4), to be fused to the N-terminus of full-length Midnolin, as C-terminal or internal insertions are ineffective. Domain dissection revealed that neither the ubiquitin-like (UBL) domain nor the alpha-helical C-terminal (αHelix-C) domain alone, nor their simple tandem, is sufficient for degradation; the intact spatial conformation of the Midnolin scaffold is essential. Notably, MidTAC efficiently degraded substrate proteins irrespective of their subcellular localization, demonstrating its broad-spectrum utility. Furthermore, fusing the VHL E3 ligase to the C-terminus of Midnolin significantly enhanced degradation efficiency, suggesting a synergistic effect between ubiquitin-independent capture and ubiquitin-dependent recruitment. Collectively, these findings provide the first systematic characterization of MidTAC configuration, domain requirements, and broad-spectrum degradability, establishing a refined framework for engineering of next-generation BioPROTACs with an expanded substrate range.</p>","PeriodicalId":6942,"journal":{"name":"Acta Pharmacologica Sinica","volume":" ","pages":""},"PeriodicalIF":10.4000,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Pharmacologica Sinica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41401-026-01959-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0

Abstract

Biological proteolysis-targeting chimeras (BioPROTACs), which employ peptide or protein-based targeting ligands to recruit endogenous degradation machinery, offer a promising strategy to expand the scope of targeted protein degradation. The recently discovered Midnolin employs a distinct, ubiquitin-independent "capture-degradation" mechanism that engages the proteasome directly, offering a complementary mechanistic strategy. However, the design principles, domain requirements, and substrate selectivity of Midnolin-based targeting chimeras (MidTAC) remain poorly understood. In this study, we systematically optimized the MidTAC platform and defined its functional boundaries. We demonstrated that optimal degradation activity requires the targeting module, the anti-GFP nanobody VHHGFP4 (variable domain of heavy chain of heavy-chain-only antibody against GFP variant 4), to be fused to the N-terminus of full-length Midnolin, as C-terminal or internal insertions are ineffective. Domain dissection revealed that neither the ubiquitin-like (UBL) domain nor the alpha-helical C-terminal (αHelix-C) domain alone, nor their simple tandem, is sufficient for degradation; the intact spatial conformation of the Midnolin scaffold is essential. Notably, MidTAC efficiently degraded substrate proteins irrespective of their subcellular localization, demonstrating its broad-spectrum utility. Furthermore, fusing the VHL E3 ligase to the C-terminus of Midnolin significantly enhanced degradation efficiency, suggesting a synergistic effect between ubiquitin-independent capture and ubiquitin-dependent recruitment. Collectively, these findings provide the first systematic characterization of MidTAC configuration, domain requirements, and broad-spectrum degradability, establishing a refined framework for engineering of next-generation BioPROTACs with an expanded substrate range.

靶向蛋白降解MidTAC平台的系统优化与表征。
生物蛋白水解靶向嵌合体(BioPROTACs)利用肽或蛋白质为基础的靶向配体来招募内源性降解机制,为扩大靶向蛋白质降解的范围提供了一种有前途的策略。最近发现的Midnolin采用了一种独特的、与泛素无关的“捕获-降解”机制,直接参与蛋白酶体,提供了一种互补的机制策略。然而,基于midnolin的靶向嵌合体(MidTAC)的设计原则、结构域要求和底物选择性仍然知之甚少。在本研究中,我们系统地优化了MidTAC平台,并定义了其功能边界。我们证明了最佳的降解活性需要靶向模块,抗GFP纳米体VHHGFP4(针对GFP变体4的仅重链抗体的重链可变结构域)融合到全长Midnolin的n端,因为c端或内部插入无效。结构域解剖表明,无论是泛素样结构域(UBL)还是α -螺旋c末端结构域(αHelix-C),或者它们的简单串联,都不足以降解;Midnolin支架完整的空间构象是必不可少的。值得注意的是,无论底物蛋白的亚细胞定位如何,MidTAC都能有效地降解底物蛋白,这证明了其广谱实用性。此外,将VHL E3连接酶融合到Midnolin的c端显著提高了降解效率,表明泛素非依赖性捕获和泛素依赖性募集之间存在协同效应。总的来说,这些发现提供了MidTAC结构、结构域要求和广谱可降解性的第一个系统表征,为扩大底物范围的下一代BioPROTACs工程建立了一个完善的框架。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Pharmacologica Sinica
Acta Pharmacologica Sinica 医学-化学综合
CiteScore
15.10
自引率
2.40%
发文量
4365
审稿时长
2 months
期刊介绍: APS (Acta Pharmacologica Sinica) welcomes submissions from diverse areas of pharmacology and the life sciences. While we encourage contributions across a broad spectrum, topics of particular interest include, but are not limited to: anticancer pharmacology, cardiovascular and pulmonary pharmacology, clinical pharmacology, drug discovery, gastrointestinal and hepatic pharmacology, genitourinary, renal, and endocrine pharmacology, immunopharmacology and inflammation, molecular and cellular pharmacology, neuropharmacology, pharmaceutics, and pharmacokinetics. Join us in sharing your research and insights in pharmacology and the life sciences.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书